论文信息 - Nodal Recurrence as Primary Driver of Early Relapse in Patients with SLN-Positive Melanoma: What Does It Mean for Providers and Patients? - 字舞流文

Nodal Recurrence as Primary Driver of Early Relapse in Patients with SLN-Positive Melanoma: What Does It Mean for Providers and Patients?

G. Beasley | K. Rhodin | Nellie Farrow

[1] Jeffrey E. Lee,et al. Nodal Recurrence is a Primary Driver of Early Relapse for Patients with Sentinel Lymph Node-Positive Melanoma in the Modern Therapeutic Era , 2021, Annals of Surgical Oncology.

[2] C. Berking,et al. Final Analysis of DeCOG-SLT Trial: No Survival Benefit for Complete Lymph Node Dissection in Patients With Melanoma With Positive Sentinel Node. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3] C. Slingluff,et al. Updates in adjuvant systemic therapy for melanoma , 2018, Journal of surgical oncology.

[4] D. Schadendorf,et al. Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma , 2018, The New England journal of medicine.

[5] A. Gesierich,et al. Completion Dissection or Observation for Sentinel‐Node Metastasis in Melanoma , 2017, The New England journal of medicine.

[6] C. Berking,et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. , 2016, The Lancet. Oncology.

[7] M. Green,et al. The microanatomic location of metastatic melanoma in sentinel lymph nodes predicts nonsentinel lymph node involvement. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.